SCHEMBL290322

SCHEMBL290322

Cc1ccc(Br)cc1C#N

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.48
MAOB P27338 3/20 0.41
MAOA P21397 2/20 0.41
ALDH1A1 P00352 3/20 0.38
SLC1A5 Q15758 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
DRD4 P21917 1/20 0.36
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36
CHEK1 O14757 1/20 0.35
AAK1 Q2M2I8 2/20 0.35
MAPK1 P28482 2/20 0.34
MCL1 Q07820 1/20 0.34
KCNH2 Q12809 1/20 0.34
LMNA P02545 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
BIRC5 O15392 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29825887 1.00 TSHR (0.48) TSHRMAOBMAOAALDH1A1SLC1A5
SCHEMBL290236 0.82 TSHR (0.48) TSHRMAOBMAOANOS3NOS1
SCHEMBL29175249 0.79 BIRC5 (0.39) TSHRMAOBMAOAALDH1A1SLC1A5
SCHEMBL30475151 0.78 MAOB (0.61) MAOBMAOAALDH1A1SLC1A5NOS3
SCHEMBL1395661 0.78 MAOB (0.61) MAOBMAOAALDH1A1SLC1A5NOS3
SCHEMBL8404526 0.78 CYP2A6 (0.42) TSHRMAOBMAOAALDH1A1NOS3
SCHEMBL13384752 0.78 LRRK2 (0.39) TSHRMAOBMAOADRD4
SCHEMBL16953356 0.77 ALDH1A1 (0.35) ALDH1A1MAPK1
SCHEMBL119203 0.77 TSHR (0.50) TSHRALDH1A1L3MBTL1
SCHEMBL1343188 0.76 MAOB (0.44) TSHRMAOBMAOAALDH1A1SLC1A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709722-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 EP disclosed
US-20260041671-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2026-02-12 US disclosed
US-12539292-B2 BRM targeting compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-03 US disclosed
US-20260008782-A1 HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION CONVELO THERAPEUTICS, INC. 2026-01-08 US disclosed
US-20250223286-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF BETTA PHARMACEUTICALS CO.,LTD (CN) 2025-07-10 US disclosed
CN-119998288-A Hydantoin modulators of cholesterol biosynthesis and their use for promoting remyelination 基因泰克公司 2025-05-13 CN disclosed
EP-4537905-A2 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2025-04-16 EP disclosed
US-12258329-B2 Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells MERCK SHARP & DOHME LLC (US) 2025-03-25 US disclosed
WO-2025056068-A1 BICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 上海济煜医药科技有限公司 2025-03-20 WO disclosed
EP-3774789-B1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2025-03-05 EP disclosed
WO-2001079261-A1 TETRAHYDRO-AZEPINONE DERIVATIVES AS THROMBIN INHIBITORS CORVAS INTERNATIONAL, INC. (US) 2001-10-25 WO disclosed
WO-2001079195-A2 PYRIDINE AND PYRAZINE DERIVATIVES AS THROMBIN INHIBITORS CORVAS INTERNATIONAL, INC. (US) 2001-10-25 WO disclosed
WO-2001079262-A1 PYRAZINONE AND PYRIDINONE DERIVATIVES AS THROMBIN INHIBITORS CORVAS INTERNATIONAL, INC. (US) 2001-10-25 WO disclosed
EP-0594019-B1 1-Biphenylmethyl-pyridone derivatives, their preparation and their use as angiotensin II antagonistes BAYER AG (DE) 2000-02-23 EP disclosed
US-5863930-A ATHEROSCLEROSIS TREATMENT FORMED BY REACTION OF PYRIDONES WITH BIPHENYLMETHYL HALOGEN BAYER AKTIENGESELLSCHAFT (DE) 1999-01-26 US disclosed
CN-1040435-C Trisubstituted biphenyls BAYER AG (DE) 1998-10-28 CN disclosed
WO-1998016526-A1 TETRAHYDRO-6H-PYRAZINO[1,2-B]ISOQUINOLINE 1,4-DIONES AS APOPROTEIN B-100 INHIBITORS GLAXO GROUP LIMITED (GB) 1998-04-23 WO disclosed
US-5596006-A ANTIHYPERTENSIVE, ANTIATHEROSCLEROTIC AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1997-01-21 US disclosed
CN-1089260-A Trisubstituted biphenyls BAYER AG (DE) 1994-07-13 CN disclosed
EP-0594019-A1 Trisubstituted biphenyl as angiotensin II antagonistes BAYER AG (DE) 1994-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250223286-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF IL2, IL5, TSLP TSHR 3037/4885MAOB 1137/4885MAOA 1592/4885
US-12539292-B2 BRM targeting compounds and associated methods of use ADRM1, SUMO2, BAZ1A TSHR 1630/4885MAOB 3959/4885MAOA 3378/4885
US-20260008782-A1 HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION SGMS1, MAG, SGMS2 TSHR 4027/4885MAOB 2326/4885MAOA 3032/4885
US-20260041671-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, VHL, BAZ1A TSHR 1673/4885MAOB 4408/4885MAOA 3904/4885
US-12258329-B2 Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells TYMP, PNP, CD4 TSHR 4499/4885MAOB 3431/4885MAOA 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.